Author:
Haraoui Boulos,Pelletier Jean-Pierre,Martel-Pelletier Johanne
Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.
2. Haraoui B, Cameron L, Ouellet M, et al.: Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006, 33:31–36.
3. Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunother 2006, 29:1–9.
4. Abbott Laboratories: Humira® (adalimumab) prescribing information. Available at http://www.rxabbort.com/pdf/humira.pdf . Accessed on May 14, 2007.
5. Cohen SB, Greenwald M, Dougados M, et al.: Efficacy and safety of Rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF alpha therapies (REFLEX Study) [abstract]. Arthritis Rheum 2005, 52:S677.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献